, (where phen is 1,10-Phenantroline, pip-dtc is piperidinedithiocarbamate anion and mor-dtc is morpholinedithiocarbamate anion) have been synthesized and characterized by elemental analysis, spectroscopic studies (FT-IR, 1 H NMR, UV-Vis) and conductance measurement. In these complexes, the dithiocarbamate ligands coordinate with Pd (II) center as bidentate with two sulfur atoms. These two complexes have been tested against chronic myelogenous leukemia cell line, K562. They show IC50 values less than cisplatin and thus the mode of binding of the complexes to calf thymus DNA (CT-DNA) were investigated by ultraviolet difference and fluorescence spectroscopy. They can denature DNA, exhibit cooperative binding and intercalate into DNA. Several binding and thermodynamic parameters are also described.
INTRODUCTION
cis-Diamminedichloroplatinum(II) (cisplatin) is one of the most effective anticancer drugs currently available for the treatment of testicular, lung and bladder carcinomas.
1-3
Despite the success of cisplatin and platinum-based drugs, the market is still accessible for new advantageous metal-based drugs that offer better viability, such as oral administration, which might help to diminish severe side effects and clinical costs. Additionally, research is focused on drugs with higher efficacy, i.e. drugs that interact differently with the target, CT-DNA, can overcome inherent or acquired cisplatin resistance in many tumors, and are active towards tumors which are non-responsive to current chemotherapy.
In order to investigate the effect of combined nitrogen and sulfur donor chelating ligands on the activity of palladium(II) complexes, we designed, synthesized and characterized two palladium complexes with the 1,10-phenanthroline and S,S chelated dithiocarbamete containing the piperidine and morpholine residue. The cytotoxicities of these complexes were tested against chronic myelogenous leukemia cell line, K562. Gel filtration, electronic absorption titration and fluorescence experiments were employed to determine the modes of binding of the above Pd(II) complexes with CT-DNA. In these interaction studies, binding parameters, thermodynamic parameters, and the type of binding between these agents and CT-DNA are also described. These parameters may throw light on the interaction mechanisms of these types of complexes with DNA of cells and possible side effects of these agents. It is speculated that this mechanism must be different from that reported for cisplatin.
EXPERIMENTAL
Material and general methods Palladium(II) chloride anhydrous, sodium chloride, NaOH and KBr were obtained from Fluka (Switzerland). Piperidine, morpholine, AgNO 3 and carbon disulfide were purchased from Aldrich (England). 1,10-phenathroline, Sephadex G-25 and Tris-HCl buffer were obtained from Merck (Germany). Calf thymus DNA and Ethidium bromide (EB) were obtained from Sigma Chemical Co. (USA) and used as received. All other solvents and reagents used were of analytical grade and purified before use by the standard methods. The doubly distilled water was used all along. [Pd(phen)Cl 2 ] were prepared by the procedures described in the literature. 15 Piperidine dithiocarbamate sodium salt (pip-dtcNa) and morpholine dithiocarbamate sodium salt (mor-dtcNa) was synthesized in our laboratory. 16, 17 All the experiments involving interaction of the complexes with CT-DNA were performed in Tris-HCl buffer (20 mM) of pH=7.0 medium containing 20 mM NaCl. Sodium choloride was used to adjust the ionic strength of the solution. Monitoring the ratio of the absorbance at 260 to that of 280 nm checks purity of CT-DNA. The solution gave a ratio of >1.8 at A 260 /A 280 , indicating that CT-DNA is sufficiently free from protein. 18, 19 The CT-DNA concentration per nucleotide was determined by absorption spectroscopy using the known molar extinction coefficient value of 6600 M -1 cm -1 at 260 nm.
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Microchemical analysis of carbon, hydrogen, and nitrogen for the complexes was carried out on Herause CHNO-RAPID elemental analyzer.
1
H NMR spectra were recorded on a Brucker DRX-500 Avance spectrometer at 500 MHz in DMSO-d6 using tetramethylsilane as internal reference. Electronic absorption spectra of the title metal complexes were measured on a J AS.CO UV/Vis-7850 recording spectrophotometer. Infrared spectra of the metal complexes were recorded on a J AS.CO -460 Plus FT-IR spectrophotometer in the range of 4000 to 400 cm -1 in KBr pellets. Fluorescence intensity measurements were carried out on a Hitachi spectrofluorimeter model MPF-4. Conductivity measurements of the above palladium complexes were carried out on a Systronics conductivity bridge 305, using a conductivity cell of cell constant 1.0. Melting points were measured on a Unimelt capillary melting point apparatus and here reported uncorrectedly. The following spectrometric measurements were all performed in a quartz cuvette of 1 cm path length. 16, 25 Electronic spectra exhibit four bands. The band at 460 (log ε = 3.17) is assigned to metal to 1,10-phenanthroline charge transfer and the other bands at 341 (ε = 3.58), 277 (ε = 4.1) and 237 (ε = 4.11) may be assigned to first, second and higher intraligand π-π* transitions of 1,10-phenanthroline ligand as well as -CSS 
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Electronic spectra exhibit four bands. The band at 341 (log ε = 6.53) is assigned to metal to 1,10-phenanthroline charge transfer and the other bands at 274 (ε = 6.44), 246 (ε = 6.39) and 208 (ε = 6.32) may be assigned to first, second and higher intraligand π-π* transitions of 1,10-phenanthroline ligand as well as -CSS -group of dithicarbamate ligand.
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Cytotoxicity assay
Cell proliferation was evaluated by using a system based on the tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT] which is reduced by living cells to yield a soluble formazan product that can be assayed colorimetrically. [26] [27] [28] The MTT assay is dependent on the cleavage and conversion of the soluble yellowish MTT to the insoluble purple formazan by active mitochondrial dehydrogenase of living cells. The leukemia cell line K562 was maintained in a RPMI medium supplemented with 10% heat-inactivated fetal calf serum and 2 mM L-glutamine, streptomycin and penicillin (5 µg/ ml), at 310 K under a 5% CO 2 /95% air atmosphere. Harvested cells were seeded into 96-well plate (2×10 4 cell/mL) with varying concentrations of the sterilized drug (0-250 µM) and incubated for 24 hours. At the end of four hours incubations 25 µL of MTT solution (5 mg/mL in PBS) was added to each well containing, fresh and cultured medium.
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The insoluble formazan produced was then dissolved in solution containing 10% SDS and 50% DMF (under dark condition for 2 h at 310 K), and optical density (OD) was read against reagent blank with multi well scanning spectrophotometer (ELISA reader, Model Expert 96, Asys Hitchech, Austria) at a wavelength of 570 nm. Absorbance is a function of concentration of converted dye. The OD value of study groups was divided by the OD value of untreated control and presented as percentage of control (as 100%). Results were analyzed for statistical significance using two tailed Student's t-test. Changes were considered significant at p < 0.05. In this experiment, the clear stock solution (2 mM, in deionized water) was sterilized by filtering through sterilizing membrane (0.1 nm) and then varying concentrations of the sterilized drug (0-25 µM) were added to harvested cells.
Spectroscopic studies on CT-DNA interaction
The experiments were carried out in Tris-HCl buffer using a solution of calf thymus DNA (4 mg/mL) at 277 K until homogenous. The stock solutions of Pd(II) complexes (0.05 mM for [Pd(phen)(pip-dtc)]NO 3 complex and 0.1 mM for [Pd(phen)(mor-dtc)]NO 3 complex) were made in TrisHCl buffer by gentle stirring and heating at 308 K. The CT-DNA-metal complex solutions were incubated at 300 K and 310 K, separately. Then, the spectrophotometric readings at λ max of the palladium complexes (300 nm) where CT-DNA has no absorption were measured. Using trial and error method, the incubation time for solutions of DNA-metal complex at 300 K and 310 K was found to be 6 hour. No further changes were observed in the absorption readings after longer incubation, indicating that interaction is completed. All the experiments repeated to get the constant results.
CT-DNA-denaturation studies and determination of thermodynamic parameters
The application of UV absorption method to the study of denaturation of CT-DNA Pd(II) complexes were similar to that reported earlier. 30, 31 In this experiment, the sample cell was filled with 1.8 mL CT-DNA (~0.20 mM for [Pd(phen)(pip-dtc)]NO 3 and ~0.17 mM for [Pd(phen) (mor-dtc)]NO 3 complexes). In these concentrations, the absorption of CT-DNA is around 1.32 and 1.12, respectively. However, reference cell is filled with 1.8 mL TrisHCl buffer only. Both cells were set separately at constant temperature of 300 K or 310 K and then 10 µL stock solution of [Pd(phen)(pip-dtc)]NO 3 or 50 µL stock solution of [Pd(phen)(mor-dtc)]NO 3 complexes, were added to each cell. After 3 min., the absorption was recorded at 260 nm for CT-DNA and at 640 nm to eliminate the interference of turbidity. Addition of metal complex to both cells was continued until no further changes in the absorption readings were observed. In these studies, the concentration of each metal complex at midpoint of transition, [L] 1/2 , was determined. Also, thermodynamic parameters such as:
, conformational stability of CT-DNA in the absence of metal complex;
, the heat needed for CT-DNA denaturation in the absence of metal complex; , the entropy of CT-DNA denaturation by metal complex as well as m, measure of the metal complex ability to denature CT-DNA were found out using Pace method.
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Electronic spectroscopy Electronic absorption titration experiments were performed with fixed concentration of each metal complex (10 µL from [Pd(phen)(pip-dtc)]NO 3 complex of 0.05 mM stock and 50 µL from [Pd(phen)(mor-dtc)]NO 3 complex of 0.1 mM stock), while gradually increasing the concentration of CT-DNA (20-55 µL for [Pd(phen)(pip-dtc)]NO 3 complex from 1.9 mM stock and 10-90 µL for [Pd(phen)(mordtc)]NO 3 complex from 2.1 mM stock) in total volume of 2 mL for obtaining the maximum ∆A (∆A max ), i.e. change in the absorbance when all binding sites on CT-DNA were occupied by metal complex. To affirm quantitatively the affinity of the complexes bound to CT-DNA, the binding parameters (n, K and g) of metal complexes to CT-DNA were obtained. n is Hill coefficient, g is the number of binding sites per 1000 nucleotides of CT-DNA and K is apparent binding constant. In this experiment, a fixed amount of CT-DNA (25 µL for [Pd(phen)(pip-dtc)]NO 3 from 1.8 mM stock and 25 µL for [Pd(phen)(mor-dtc)]NO 3 complex from 2.9 mM stock) was titrated with varying concentrations of each of Pd (II) complexes (125-258 µL for [Pd(phen)(pip-dtc)]NO 3 from 0.05 mM stock and 50-150 µL for [Pd(phen)(mor-dtc)]NO 3 from 0.1 mM stock) in total volume of 2 mL. Each sample solution was scanned at 300 nm for two complexes.
Fluorescence spectroscopy
Quantitatively the affinity of the compounds bound to CT-DNA compared by the luminescence titration method. In this experiment, a series of solutions with various concentrations of each of the two complexes (1.78-2.55 for [Pd(phen)(pip-dtc)]NO 3 and 2.44-4.67 for [Pd(phen)(mordtc)]NO 3 ) were added to a solution of CT-DNA (60 µM) and ethidium bromide (2 µM). The samples were excited at 471 nm and emission was observed between 540 and 700 nm at 300 K and 310 K temperatures. The fluorescence intensities of the Pd(II) complexes at the highest denaturant concentration at 471 nm excitation wavelength have been checked, and the emission intensities of these compounds were very small and negligible.
Further studies to characterize the mode of binding of Pd(II) to CT-DNA were carried out by Scatchard analysis. 33 In this experiment, the wavelengths of excitation and emission were set at 540 nm and 700 nm respectively. Both have 0.5 nm slit widths. Solutions of CT-DNA, EB and metal complexes were prepared in Tris-HCl buffer of pH 7.0. In this medium solutions of Pd(II) complexes were interacted with CT-DNA by incubating them at 300 K for 6 h, appropriate amount of EB was then added to them and further incubated at room temperature (300 K) for 6 h and finally processed for fluorescence spectral measurement. 
Gel filtration
Each of the above mentioned Pd(II) complexes (500 µM) was incubated with calf thymus DNA (77.4 µM for [Pd(phen) (pip-dtc)]NO 3 complex and 230.95 µM for [Pd(phen) (mor-dtc)]NO 3 complex) for 6 h at 301 K in Tris-HCl buffer (pH 7.0). It was then passed through a Sephadex G-25 column equilibrated with the same buffer. The elusion of the column fraction of 2.0 mL was monitored at 300 nm and 260 nm for DNA-Pd(II) complexes. Gel chromatograms are obtained by plotting of absorbance readings at the two wavelengths versus column fractions in the same plot. In this plot, the two peaks obtained may resolve or not. The former indicates that the CT-DNA is separated from the metal complex and the binding of CT-DNA to metal complex is weak and reversible. However, if the two peaks are not resolved, it indicates that the CT-DNA is not separated from the metal complex and the binding is stronger and irreversible.
RESULTS AND DISCUSSION
Cytotoxicity screenings
The effect of prepared complexes on human leukemic K562 cells was evaluated by MTT assay. In this study, various concentrations of Pd (II) complexes ranging from 0 to 25 µM of stock solution (2 mM) were used to culture the tumor cell lines for 24 h. The Ic 50 value of the [Pd(phen) (pip-dtc)]NO 3 and the [Pd(phen)(mor-dtc)]NO 3 complexes are 0.22 mM. As shown in Fig. 1 These results suggest that the two complexes may be potential antitumor agent.
CT-DNA-binding studies CT-DNA denaturation data evaluation of thermodynamic parameters: Electronic absorption spectroscopy is one of the most useful techniques for CT-DNAbinding studies of metal complexes. 34, 35 The result of UVVis spectrum analysis about the interaction of CT-DNA with Pd(II) complexes is shown in Fig. 2 with CT-DNA. It is noticeable that, absorbance of DNA bases (purines and pyrimidines) decrease as their ring systems become parallel and near to one another, more stacking. Thus decrease in the absorbance at 260 nm with increase of amount of Pd(II) complexes added to CT-DNA may be due to: (i) a possibility that interaction between CT-DNA and the metal complex causes the double helix of CT-DNA to become more straight leading to stacking. This stacking may cause conformational changes leading to a sort of denaturation, or (ii) each strand after denaturation get associated in a more stacked structure and (iii) metal complex slips into the helix and masks the hydrophobic bases leading to a decrease in absorbance. As will be seen in the later part of this paper, the palladium(II) complexes can bind CT-DNA taking the mode of intercalation. This mode of binding supports the above three hypothesis.
Furthermore, some thermodynamic parameters found in the process of CT-DNA denaturation are discussed here: Using the CT-DNA denaturation plots given in Fig. 2 Here the values of for each curve are measured from the intercept on ordinate of the plots and it is conformational stability of DNA in the absence of metal complex. m (the slope of each curve in the same plots) is a measure of the metal complex ability to denature CT-DNA and are summarized in Table 1 . The values of m for the above complexes are much higher than those of Pt(II) and Pd(II) complexes reported earlier, 16, 39, 40 which indicate the higher ability of [Pd(phen)(pip-dtc)]NO 3 and [Pd(phen) (mor-dtc)]NO 3 complexes to denature CT-DNA. As we know, the higher the value of G, the larger the conformational stability of CT-DNA. However, the values of ∆G o (Table 1) are decreased by increasing the temperature for both the complexes. This is as expected because in general, the decrease in value is the main reason for the decrease in CT-DNA stability. 42 The values of m for [Pd(phen)(pip-dtc)]NO 3 complex are higher than that of [Pd(phen)(mor-dtc)]NO 3 complex which indicate the higher ability of [Pd(phen) (pip-dtc)]NO 3 complex to denature CT-DNA. Another important thermodynamic parameter found is the molar enthalpy of CT-DNA denaturation in absence of metal complexes i.e.
. For this, we calculated the molar enthalpy of CT-DNA denaturation in the presence of metal complexes, ∆H o conformation or ∆H o denaturation , in the range of the two temperature using Gibbs-Helmholtz equation. 43 On plotting the values of these enthalpies versus the concentrations of metal complexes, straight lines will be obtained which are shown in Fig. 4 for [Pd(phen)(pip-dtc)]NO 3 complex and the inset of [Pd(phen)(mor-dtc)]NO 3 complex. Intrapolation of these lines (intercept on ordinate i.e. absence of metal complex) give the values of ( Table 1 ). These plots show that in the range of 300 K and 310 K the changes in the enthalpies in the presence of [Pd(phen)(mor-dtc)]NO 3 complex is descending. These observations indicate that on increasing the concentration of this complex, the stability of CT-DNA is decreased. In addition, the entropy ( ) of CT-DNA unfolding by Pd(II) complexes have been calculated using equation
o and the data are given in Table 1 . These data show that the metal -DNA complexes are more disordered than that of native CT-DNA, because the entropy changes are positive for [Pd(phen)(pipdtc)]NO 3 -DNA complex as well as [Pd(phen)(mor-dtc)] NO 3 -DNA complex in the interaction of CT-DNA (Table 1) .
Electronic spectral studies and determination of binding parameters
Absorption spectral titration experiment was performed by keeping the concentration of the drugs constant while varying the CT-DNA concentrations. In this experiment, change in absorbance, A, was calculated by subtracting the absorbance reading of mixed solutions of each metal complex with various concentrations of CT-DNA, from absorbance reading of free metal complex. The values of ∆A max , change in absorbance when all binding sites on CT-DNA were occupied by metal complex, are given in Table 2 Conformational stability of CT-DNA in the absence of metal complex. (M) fixed amount of CT-DNA with varying amount of each metal complex. Using these data (v, [L] f ), the Scatchard plots 44 were constructed for the interaction of metal complexes at the two temperatures 300 K and 310 K. The Scatchard plots are shown in Fig. 6 for [Pd(phen)(pip-dtc)]NO 3 complex and the inset for [Pd(phen)(mor-dtc)]NO 3 complex. These plots are curvilinear concave downwards, suggesting cooperative binding. 33 To obtain the binding parameters, the above experimental data (v and [L] f ) were substituted in equation (4) 
Thus, we get a series of equation with unknown parameters n, K and g. Using Eureka software, the theoretical values of these parameters could be deduced ( Table 2) . The values of n for two complexes will be more than 1, which means that the systems are cooperative thus, the binding at one site increases the affinity of others. . 48 Obviously, these spectral characteristics suggest that the two complexes intercalatively bind to CT-DNA, involving a strong stacking interaction between the aromatic chromophore (1,10-phenanthroline present in the structure of complexes) and the base pairs of the DNA. 49 The maximum errors between experimental and theoretical values of v are also shown in Table 2 (mor-dtc)]NO 3 complex at 300 K. Deflections are observed in both plots which may be due to binding of metal complexes to macromolecule or macromolecule denaturation. Similar observations can be seen in the literature where Pd(II) and Pt(II) complexes have been interacted with CT-DNA.
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Fluorescent spectral studies No fluorescence was observed for the above palladium(II) complexes at room temperature in aqueous solution or in the presence of calf thymus DNA. So the binding of palladium(II) complexes and CT-DNA cannot be directly presented in the emission spectra. Hence, competitive ethidium bromide (EB) binding studies were undertaken to gain support for the extent of binding of palladium (II) complexes with CT-DNA. The molecular fluorophore, EB, emits intense fluorescence light in the presence of CT-DNA due to its strong intercalation between the adjacent CT-DNA base pairs. The results of the emission titration for the two complexes with helix CT-DNA that are illustrated in the titration curves are shown in Fig. 9 for [Pd(phen)(pip-dtc)]NO 3 complex and the inset of [Pd(phen) (mor-dtc)]NO 3 complex. Fig. 9 showed the emission spectra of DNA-EB system with increasing amounts of the Pd(II) complexes. The observation reflected that the stronger enhancement for Pd(II) complexes may be largely due to the increase of the molecular planarity of the complex and the decrease of the collision frequency of the solvent molecules with the complex which caused by the planar aromatic group of the complex stacks between adjacent base pairs of CT-DNA. The increase in the molecular planarity and the decrease of the collision frequency between solvent molecules with the complexes usually lead to emission enhancement. 51, 52 The binding of Pd(II) complexes to CT-DNA leading to marked increase in emission intensity also agrees with those observed for other intercalators.
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Further studies to characterize the mode of binding of [Pt(Oct-dtc)(bpy)]NO 3 and [Pd(Oct-dtc)(bpy)]NO 3 to DNA were carried out. 54, 55 The number of EB molecules intercalated to CT-DNA in presence of different concentrations of the Pd(II) complexes was calculated using Scatchard analysis. 44, 56 The fluorescence Scatchard plots obtained for binding of EB to CT-DNA in absence (◇) and presence (◆, ▲, •) of various concentrations of Pd(II) complexes were shown in Fig. 10 . Consequently, it might be concluded that the Pd(II) complexes inhibit competitively the EB binding to CT-DNA (type-A behavior), 44 where number of intercalated molecules per 1000 nucleotide, (intercept on the abscissa) remain constant and the slope of the graphs that is K app (apparent association constant) decrease with increasing the concentration of the complexes. The K app values for the Pd(II) complexes are listed in 
CT-DNA binding mode
The solution of each interacted CT-DNA−metal complex was passed through a Sephadex G-25 column equilibrated with Tris-HCl buffer. Elution was done with buffer and each fraction of the column was monitored spectrophotometrically at 300 nm and 260 nm for Pd(II)-CT-DNA systems. These results are given in Fig. 11 for [Pd(phen)(pipdtc)]NO 3 complex and the inset of [Pd(phen)(mor-dtc)]NO 3 complex. These plots show that the peak obtained for the two wavelengths are not resolved and suggests that CT-DNA has not separated from the metal complexes. Thus, it implies that the binding between CT-DNA and the metal complexes are not reversible under such circumstances. If the interaction between CT-DNA and metal complexes were weak, the CT-DNA should have come out of the column separately.
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CONCLUSION
In summary, the two new water soluble palladium(II) complexes have been synthesized and characterized. The interactions of the two palladium(II) complexes with calf thymus DNA (CT-DNA) are investigated by using absorption and emission spectra and gel filtration techniques. Cytotoxic studies show that the two complexes exhibit good cytotoxic activity against chronic myelogenous leukemia cell line, K562, tested. The results suggest that both the two complexes interact with CT-DNA cooperatively in the mode of intercalation and the binding ability of the [Pd(phen)(pip-dtc)]NO 3 complex to CT-DNA is more than [Pd(phen)(mor-dtc)]NO 3 complex. Several binding and thermodynamic parameters have been determined, which may be useful to understand the mechanism of interaction of this type of compounds with CT-DNA or their antitumor activities. Gel filtration results show that the two peaks obtained at two wavelengths were not clearly resolved which indicate that metal complexes have not separated from CT-DNA and their binding with CT-DNA is strong enough that not readily break. Results obtained from our present work would be useful to understand the mechanism of interactions of the small molecule compounds binding to CT-DNA and helpful in the development of their potential biological, pharmaceutical and physiological implications in the future. 
